Loading cancer entity…
Loading cancer entity…
Clinical trials
6,746 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,045)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01337154 | First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung Cancer | terminated | Phase 2 | 140 | CytRxINDUSTRY | 6 | Jun 28, 2013 | clinicaltrials |
| NCT00600587 | Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 24 | Guangdong Provincial People's HospitalOTHER | 1 | Jun 25, 2013 | clinicaltrials |
| NCT00773383 |
| terminated |
| Phase 2 |
| 35 |
| Hoffmann-La RocheINDUSTRY |
| 4 |
| Jun 24, 2013 |
| clinicaltrials |
| NCT00871403 | Study of Pazopanib and Pemetrexed in Advanced Non-small Cell Lung Cancer | completed | Phase 2 | 107 | GlaxoSmithKlineINDUSTRY | 2 | Jun 20, 2013 | clinicaltrials |
| NCT00536640 | Inoperable Non-Squamous NSCLC Stage III/IV: A Randomised Phase II Study With Bevacizumab Plus Erlotinib Or Gemcitabine/Cisplatin Plus Bevacizumab(INNOVATIONS) | completed | Phase 2 | 224 | Aktion Bronchialkarzinom e.V.OTHER | 1 | Jun 12, 2013 | clinicaltrials |
| NCT01872403 | Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage Ⅱ B and IIIA Squamous Cell Carcinoma of the Lung | unknown | Phase 2 | 120 | The First Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 7, 2013 | clinicaltrials |
| NCT00062101 | Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00087269 | Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection | terminated | Phase 2 | 110 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2013 | clinicaltrials |
| NCT00040794 | Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | completed | Phase 2 | 144 | National Cancer Institute (NCI)NIH | 1 | Jun 5, 2013 | clinicaltrials |
| NCT00006929 | Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | completed | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00055757 | Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00118183 | Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00758134 | Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients | terminated | Phase 2 | 9 | Armando Santoro, MDOTHER | 1 | May 29, 2013 | clinicaltrials |
| NCT00855894 | A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer(PENGUIN) | completed | Phase 2 | 41 | Genentech, Inc.INDUSTRY | 2 | May 21, 2013 | clinicaltrials |
| NCT00716534 | Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 145 | AbbVie (prior sponsor, Abbott)INDUSTRY | 6 | Apr 29, 2013 | clinicaltrials |
| NCT00268255 | Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Barbara Ann Karmanos Cancer InstituteOTHER | 0 | Apr 16, 2013 | clinicaltrials |
| NCT00517790 | Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 140 | AbbVie (prior sponsor, Abbott)INDUSTRY | 5 | Apr 5, 2013 | clinicaltrials |
| NCT00865319 | Phase 2 Study Comparing 99mTc-EC-DG SPECT/CT With 18F FDG PET/CT in Patients With Non-small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 22 | Cell>Point LLCINDUSTRY | 2 | Mar 22, 2013 | clinicaltrials |
| NCT01795768 | Proof-of-Concept Study of AZD4547 in Patients With FGFR1 or FGFR2 Amplified Tumours(FGFR) | unknown | Phase 2 | 48 | Royal Marsden NHS Foundation TrustOTHER | 1 | Mar 15, 2013 | clinicaltrials |
| NCT01088620 | Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer | suspended | Phase 2 | 134 | WiSP Wissenschaftlicher Service Pharma GmbHOTHER | 1 | Mar 14, 2013 | clinicaltrials |
| NCT01802021 | Effect of Astragalus-based Formula: Qingshu-Yiqi-Tang on Modulating Immune Alterations in Lung Cancer Patients(QSYQT) | unknown | Phase 2 / Phase 3 | 120 | Chang Gung Memorial HospitalOTHER | 1 | Mar 1, 2013 | clinicaltrials |
| NCT00029003 | Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer | completed | Phase 2 | 90 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00075751 | Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 | 99 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00087412 | S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer | completed | Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00777309 | A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 2 | 167 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 6 | Feb 28, 2013 | clinicaltrials |
| NCT00021060 | Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer | completed | Phase 2 / Phase 3 | 842 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00077350 | A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer | completed | Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Feb 27, 2013 | clinicaltrials |
| NCT00824746 | Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)(ReGaiN) | completed | Phase 2 | 23 | Chonnam National University HospitalOTHER | 1 | Feb 26, 2013 | clinicaltrials |
| NCT01796288 | The Value of Radiotherapy in the Oligometastatic Non-squamous Non-small Cell Lung Cancer With Clinical Benefits From Erlotinib as Second-line Treatment(ROLE) | unknown | Phase 2 | 200 | Wu Jieping Medical FoundationOTHER | 1 | Feb 21, 2013 | clinicaltrials |
| NCT00550173 | A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer | completed | Phase 2 | 247 | Eli Lilly and CompanyINDUSTRY | 7 | Feb 13, 2013 | clinicaltrials |
| NCT00705549 | Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer | terminated | Phase 2 | 88 | Hellenic Oncology Research GroupOTHER | 1 | Feb 13, 2013 | clinicaltrials |
| NCT00265317 | A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone(SUN1058) | completed | Phase 2 | 162 | PfizerINDUSTRY | 8 | Feb 6, 2013 | clinicaltrials |
| NCT00280787 | Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim | completed | Phase 2 | 24 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2013 | clinicaltrials |
| NCT00297089 | A Phase 1/2 Study Evaluating ABT-751 in Combination With Alimta in Advanced Non-Small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 165 | AbbVie (prior sponsor, Abbott)INDUSTRY | 6 | Jan 31, 2013 | clinicaltrials |
| NCT00391248 | Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL) | completed | Phase 2 | 40 | Ontario Clinical Oncology Group (OCOG)OTHER | 1 | Jan 29, 2013 | clinicaltrials |
| NCT01196234 | Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung Cancer(PRIDE) | completed | Phase 2 | 84 | Asan Medical CenterOTHER | 1 | Jan 29, 2013 | clinicaltrials |
| NCT01510990 | First Line Gefitinib by FDG-PET Metabolic Response | unknown | Phase 2 | 60 | Asan Medical CenterOTHER | 1 | Jan 29, 2013 | clinicaltrials |
| NCT00074022 | GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors | completed | Phase 1 / Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT01770795 | A Phase II Trial of Genexol-PM and Gemcitabine in Patients With Advanced Non-small-cell Lung Cancer | completed | Phase 2 | 45 | Gachon University Gil Medical CenterOTHER | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00387374 | Radiation Therapy, Bevacizumab, Paclitaxel, and Carboplatin in Treating Patients With Unresectable Stage IIIB or Stage IV Non-Small Cell Lung Cancer at High Risk for Hemoptysis Caused by Bevacizumab | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 0 | Jan 17, 2013 | clinicaltrials |
| NCT00004883 | Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2 | completed | Phase 2 | 84 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00040768 | Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00862134 | Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 2 | 42 | Proacta, IncorporatedINDUSTRY | 3 | Jan 10, 2013 | clinicaltrials |
| NCT00063895 | Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and Neck | completed | Phase 1 / Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2013 | clinicaltrials |
| NCT00050674 | Docetaxel and Gemcitabine With Filgrastim-SD/01 Support in Patients With Advanced Non-Small Cell Lung Carcinoma | completed | Phase 2 | 40 | Schwartzberg, Lee, M.D.INDIV | 1 | Dec 27, 2012 | clinicaltrials |
| NCT01755923 | Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC | unknown | Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Dec 24, 2012 | clinicaltrials |
| NCT01749072 | Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients | unknown | Phase 2 | 120 | Peking Union Medical College HospitalOTHER | 1 | Dec 13, 2012 | clinicaltrials |
| NCT00379665 | Intratumoral Cancer Chemotherapy Through a Flexible Bronchoscope as an Adjunct to Brachytherapy | completed | Phase 2 | 25 | Southwestern Regional Medical CenterOTHER | 1 | Dec 11, 2012 | clinicaltrials |
| NCT00891579 | Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations | completed | Phase 2 | 161 | Chinese Society of Lung CancerOTHER | 1 | Dec 10, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Jun 28, 2013source: clinicaltrials